Connection

Campbell McInnes to Structure-Activity Relationship

This is a "connection" page, showing publications Campbell McInnes has written about Structure-Activity Relationship.
  1. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433.
    View in: PubMed
    Score: 0.177
  2. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
    View in: PubMed
    Score: 0.174
  3. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. ChemMedChem. 2020 06 17; 15(12):1058-1066.
    View in: PubMed
    Score: 0.157
  4. Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. J Med Chem. 2019 04 25; 62(8):3886-3897.
    View in: PubMed
    Score: 0.146
  5. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy. Bioorg Med Chem Lett. 2016 08 01; 26(15):3754-60.
    View in: PubMed
    Score: 0.120
  6. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors. J Vis Exp. 2015 Oct 26; (105):e52441.
    View in: PubMed
    Score: 0.115
  7. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem. 2015 Jan 08; 58(1):433-42.
    View in: PubMed
    Score: 0.108
  8. Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors. Bioorg Med Chem. 2014 Jan 01; 22(1):616-22.
    View in: PubMed
    Score: 0.100
  9. Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly. J Med Chem. 2013 Feb 28; 56(4):1573-82.
    View in: PubMed
    Score: 0.095
  10. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Ther. 2012 Aug; 11(8):1683-92.
    View in: PubMed
    Score: 0.092
  11. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol. 2010 Dec 17; 5(12):1169-82.
    View in: PubMed
    Score: 0.081
  12. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2006 Nov; 2(11):608-17.
    View in: PubMed
    Score: 0.061
  13. Improved lead-finding for kinase targets using high-throughput docking. Curr Opin Drug Discov Devel. 2006 May; 9(3):339-47.
    View in: PubMed
    Score: 0.059
  14. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs. 2006 Apr; 9(4):273-8.
    View in: PubMed
    Score: 0.059
  15. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol. 2004 Apr; 11(4):525-34.
    View in: PubMed
    Score: 0.051
  16. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents. 2003 Jan; 3(1):57-69.
    View in: PubMed
    Score: 0.047
  17. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925.
    View in: PubMed
    Score: 0.042
  18. Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2016 11 15; 26(22):5573-5579.
    View in: PubMed
    Score: 0.031
  19. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors. J Med Chem. 2010 Mar 11; 53(5):2136-45.
    View in: PubMed
    Score: 0.019
  20. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. ChemMedChem. 2009 Jul; 4(7):1120-8.
    View in: PubMed
    Score: 0.018
  21. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86.
    View in: PubMed
    Score: 0.018
  22. Protein structures in virtual screening: a case study with CDK2. J Med Chem. 2006 Jan 12; 49(1):92-104.
    View in: PubMed
    Score: 0.015
  23. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. Bioorg Med Chem Lett. 2004 Aug 16; 14(16):4237-40.
    View in: PubMed
    Score: 0.013
  24. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem. 2004 Mar 25; 47(7):1662-75.
    View in: PubMed
    Score: 0.013
  25. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure. 2003 Dec; 11(12):1537-46.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.